세계의 대사장애 치료제 시장 : 치료 분류, 질환 유형, 치료 영역, 투여 경로, 환자층, 최종사용자, 유통 채널별 - 예측(2025-2030년)

The Metabolic Disorders Therapeutics Market was valued at USD 69.84 billion in 2023 and is projected to grow to USD 75.55 billion in 2024, with a CAGR of 8.35%, reaching USD 122.49 billion by 2030.

In the current landscape of healthcare innovation, metabolic disorders therapeutics have emerged as a critical focus area for researchers, clinicians, and policymakers. The unprecedented convergence of advanced scientific research and clinical applications has driven a renewed interest in effective treatment modalities for metabolic and endocrine disorders. As scientific breakthroughs continue to chart new territories in genetic editing, enzyme regulation, and personalized medicine, the dialogue between regulatory bodies and healthcare providers has matured. This executive summary delves into the transformative trends that are reshaping the therapeutic landscape, the nuanced segmentation of patient needs and disease intricacies, and the competitive dynamics among leading industry players. A comprehensive understanding of these elements is essential for stakeholders looking to navigate complexities, optimize resource allocation, and leverage emerging opportunities within this dynamic market.

The narrative that follows provides a holistic view of market trends and defines the strategic imperatives for both established industry giants and emerging participants. Drawing upon recent advancements and market data, this analysis articulates the evolution of metabolic disorders therapeutics from traditional approaches to modern, patient-centric solutions. It is an invitation to explore the interplay of rigorous scientific inquiry with robust market strategies and offers decision-makers a roadmap to drive sustainable growth in a rapidly advancing sector.

Transformative Shifts Shaping the Therapeutic Landscape

Recent years have witnessed transformative shifts in the metabolic disorders therapeutics landscape, largely propelled by innovations in biomedical research and shifts in regulatory frameworks. The advent of personalized medicine and the integration of digital technologies have accelerated the evolution from conventional treatment paradigms to more targeted therapeutic approaches. The market has experienced significant change driven by developments in both molecular biology and real-world evidence, which in turn have influenced treatment protocols and clinical best practices. Scientific advances in gene therapies, enzyme replacement therapies, and small molecule interventions have collectively contributed to streamlined patient care and improved clinical outcomes.

Technological breakthroughs in genetic sequencing and bioinformatics have enabled researchers to dissect disease mechanisms at a granular level, leading to the discovery of novel biomarkers and therapeutic targets. These innovations have dramatically shortened the cycle from research to product commercialization. As treatment protocols are honed to address complex metabolic disorders, the convergence of data analytics and patient monitoring is steadily redefining therapeutic landscapes. The integration of multidisciplinary insights has created opportunities for designing robust treatment regimens that are both efficacious and cost-effective, aligning with the strategic priorities of healthcare systems globally.

Furthermore, evolving regulatory policies have fostered an environment where rapid innovation is encouraged. Enhanced collaboration between academic institutions, research organizations, and clinical practitioners paves the way for faster approval cycles and broader patient access to cutting-edge therapeutics. This shift from siloed research initiatives to more integrated, cross-functional strategies ensures that treatment modalities are not only innovative but are also supported by a resilient infrastructure capable of scaling with market demands.

Key Insights from Market Segmentation Analysis

A deep-dive segmentation analysis uncovers important insights that provide a nuanced understanding of market dynamics. The study examines treatment strategies through the lens of various classifications, such as enzyme replacement therapies, gene therapies, medications and drugs, and small molecule therapy. This diverse range of treatment modalities illustrates the breadth and depth of recent innovations in addressing metabolic disorders. It is observed that the focus on treatment classifications speaks volumes about the evolving therapeutic mechanisms aimed at enhancing patient outcomes and tailoring healthcare interventions to individualized needs.

Simultaneously, an examination by disease type reveals the comprehensive nature of market analysis. Conditions like Diabetes Mellitus, with its subdivisions into gestational diabetes, Type 1 diabetes, and Type 2 diabetes, underscore the need for specialized treatment pathways. Additionally, the study encompasses a spectrum of disorders including Gaucher's Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, and a range of thyroid disorders that are further segmented into hyperthyroidism and hypothyroidism. Other notable conditions such as urea cycle disorders and Wilson's Disease are also rigorously explored to identify the unique challenges and therapeutic opportunities associated with each condition.

The segmentation further extends to therapeutic areas, underlining diseases predominantly affecting endocrine systems, genetic frameworks, and nutritional balance. Insights drawn from this section indicate that the variety of therapeutic avenues is directly linked to a diversified portfolio of treatment modalities that can be tailored to the severity and progression of metabolic disorders. An additional layer of segmentation based on the route of administration-be it intravenous, oral, or subcutaneous-provides an understanding of patient convenience and drug efficacy. The analysis also reflects upon patient demographics by considering differences among adult, geriatric, and pediatric populations. In addition, a focus on the end user, which spans clinics, home care settings, hospitals, and specialty centers, further refines strategies for product distribution and accessibility.

A comprehensive evaluation includes the assessment of distribution channels as well, encompassing hospital pharmacies, online pharmacies, and retail pharmacies. Each of these dimensions offers rich insights that, when collectively analyzed, reveal underlying trends influencing market growth. The detailed segmentation approach not only accentuates the granular aspects of treatment discovery but also charts out a roadmap for strategic investments in research and development, ensuring that therapeutic innovations align closely with patient-centric outcomes.

Based on Treatment Classifications, market is studied across Enzyme Replacement Therapies, Gene Therapies, Medications & Drugs, and Small Molecule Therapy.

Based on Disease Type, market is studied across Diabetes Mellitus, Gaucher's Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, Thyroid Disorders, Urea Cycle Disorders, and Wilson's Disease. The Diabetes Mellitus is further studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes. The Thyroid Disorders is further studied across Hyperthyroidism and Hypothyroidism.

Based on Therapeutic Areas, market is studied across Endocrine Disorders, Genetic Disorders, and Nutritional Disorders.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Subcutaneous.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Specialty Centers.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Dynamics and Global Market Insights

A regional analysis in the metabolic disorders therapeutics market reveals significant variances in demand, market maturity, and the pace of innovation. In regions such as the Americas, advanced healthcare infrastructure and high patient awareness have fueled strong adoption rates of new therapeutics. This region is characterized by a robust blend of clinical research, increased investment in pharmaceutical development, and proactive regulatory environments that collectively expedite the path from laboratory to market.

Conversely, the landscape in Europe, the Middle East, and Africa is marked by a balance between innovative therapies and traditional treatment modalities. In these areas, a multi-faceted strategy is observed where healthcare systems are progressively integrating modern treatment options with established protocols. The interaction between regulatory changes and evolving patient demographics offers a unique perspective that emphasizes the need for customization in therapeutic development. Incentives provided by both government and regional entities have supported the growth trajectory, while challenges include aligning new treatments with regional health priorities.

The Asia-Pacific region, on the other hand, is witnessing rapid modernization in healthcare facilities coupled with a surge in patient demand for advanced therapeutics. This region demonstrates a dynamic interplay between high population density and escalating incidences of metabolic disorders, driving significant market potential. Increasing investment in infrastructure and technology in these markets is a testament to the rising importance of metabolic disorders therapeutics globally. As regional collaborations expand and international partnerships flourish, the pace of market penetration is expected to accelerate, further bridging the gap between high-demand areas and advanced treatment capabilities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Key Industry Players

The competitive landscape in metabolic disorders therapeutics is both vibrant and highly concentrated, with numerous established players exerting significant influence over market dynamics. Industry leaders, including Abbott Laboratories, AbbVie Inc., and Acadia Pharmaceuticals Inc., have leveraged their extensive research portfolios to drive innovation in treatment development. Amgen Inc. and Amicus Therapeutics, Inc. are renowned for their pioneering works in biologic therapies, while Astellas Pharma Inc. and AstraZeneca plc continue to redefine treatment paradigms through sustained investment in research and development.

Other influential companies such as Bayer AG, Biocon Limited, and BioMarin Pharmaceutical Inc. have established themselves as frontrunners in addressing rare and complex metabolic disorders. Boehringer Ingelheim International GmbH and CHIESI Farmaceutici S.p.A. demonstrate the power of cross-functional strategies and global partnerships in expanding therapeutic reach. Similarly, Dr. Reddy's Laboratories Ltd. and Eli Lilly and Company have made noteworthy strides by integrating cutting-edge technology with clinical precision. Firms like F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, and Glenmark Pharmaceuticals Limited are at the forefront of delivering improved care regimens across diverse patient groups.

The landscape is further enriched by contributions from Johnson & Johnson Services, Inc., Lupin Limited, and Luye Pharma Group Ltd, who continue to push the boundaries of therapeutic innovation. The dominance of Merck & Co., Inc., Novartis AG, and Novo Nordisk A/S is evident in their strategic market positioning and commitment to addressing multiple facets of metabolic disorders. With companies such as Otsuka Holdings Co., Ltd., Pfizer Inc., and Recordati Industria Chimica e Farmaceutica S.p.A. prioritizing research into disease-specific therapies, the market has become a crucible of competitive innovation. Additional significant contributors include Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd., whose efforts further underscore the collective drive toward improved patient outcomes and clinical efficacy.

The synergy between these industry leaders fosters a competitive yet collaborative environment, which promises to sustain momentum and drive meaningful advancements in metabolic disorders therapeutics. This confluence of expertise and innovation ensures that the market remains resilient, dynamic, and capable of responding to evolving healthcare challenges through targeted and transformative strategies.

The report delves into recent significant developments in the Metabolic Disorders Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Acadia Pharmaceuticals Inc., Amgen Inc., Amicus Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biocon Limited, BioMarin Pharmaceutical Inc., Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lupin Limited, Luye Pharma Group Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A, Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd.. Actionable Strategies and Recommendations for Industry Leaders

Given the rapidly evolving nature of the metabolic disorders therapeutics market, industry leaders must adopt a proactive stance to maintain a competitive edge and drive sustainable growth. A key recommendation is to allocate resources toward strategic investments in research and development, particularly in areas that elucidate complex disease mechanisms and pave the way for innovative treatment protocols. Embracing collaborative alliances across academic institutions, biotech startups, and pharmaceutical giants can accelerate the pace of drug discovery and help mitigate the risks associated with clinical trial failures.

Leaders would benefit from harnessing the power of digital transformation to streamline patient engagement and enhance drug delivery systems. Incorporating data analytics and artificial intelligence into research processes can not only optimize clinical trials but also tailor treatments to individual patient profiles. As the market shifts towards personalized medicine, technology-driven strategies become essential to identifying potential treatment efficacies and predicting real-world outcomes.

To expand market reach, it is imperative to diversify distribution strategies by increasing the presence in both traditional and digital channels. Establishing robust networks that connect hospital settings, homecare environments, and specialty centers ensures broader patient access. Moreover, proactive engagement with regulatory bodies to secure favorable guidelines and expedited approval processes for innovative therapies can significantly reduce time-to-market. Industry leaders should closely monitor evolving healthcare policies and align their long-term strategies to accommodate emerging legal and ethical parameters.

Lastly, staying abreast of evolving patient demographics and lifestyle trends is crucial. An in-depth understanding of the diverse needs of adult, geriatric, and pediatric populations can guide product customization and ensure a better fit with the targeted therapeutic segments. By combining strategic foresight with agile operational models, companies are better poised to adapt to market changes and secure a leadership position in this increasingly competitive field.

Conclusion: Charting the Future of Metabolic Disorders Therapeutics

In summary, the metabolic disorders therapeutics market is undergoing a period of extensive transformation driven by rapid technological advancements and evolving patient-centric treatment strategies. The integration of novel therapies, refined segmentation insights, and robust regional dynamics has redefined the landscape in ways that not only improve clinical outcomes but also enhance overall market efficiency. The detailed analysis provided here underscores the importance of innovation, collaboration, and strategic resource allocation in addressing the multifaceted challenges posed by metabolic disorders.

The discussion has highlighted the critical role of segmentation in illuminating key market drivers, including treatment classifications, disease types, therapeutic areas, and patient demographics, which collectively shape the future trajectory of the industry. Furthermore, the examination of regional trends reveals diverse opportunities-ranging from the advanced healthcare ecosystems of the Americas and the balanced approach of Europe, the Middle East, and Africa to the burgeoning potential of the Asia-Pacific region. Industry leaders and innovators are thus encouraged to draw upon these insights to forge strategies that are both adaptive and forward-thinking.

This analysis concludes that the confluence of technological innovation, strategic partnerships, and evolving market dynamics provides a fertile ground for substantial growth. To harness this potential, stakeholders must be agile, informed, and prepared to invest in the long-term sustainability of therapeutic advancements for metabolic disorders.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Shifting lifestyle and dietary patterns contributing to increased incidence of metabolic disorders
    • 5.1.1.2. Rising government initiatives and support for metabolic disorders research
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with product recall and adverse findings in medication
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in CRISPR-Cas9 and other genome-editing tools for treating metabolic disorders
    • 5.1.3.2. Growing potential with increasing collaborations and investments among pharmaceutical companies and healthcare providers
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to patent expirations and the complexity of obtaining and maintaining intellectual property
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Classifications: Increasing benefits of metabolic disorders therapeutics for gene therapies
  • 5.2.2. Disease Type: Proliferating significance of oral medications for treatment of diabetes mellitus
  • 5.2.3. Therapeutic Areas: Growing potential of metabolic disorders therapeutics for the treatment of endocrine disorders
  • 5.2.4. Route Of Administration: Significant advantages of intravenous for drugs that are poorly absorbed orally
  • 5.2.5. Patient Demographics: Increasing application of metabolic disorders therapeutics in adult patients owing to preventing progression through lifestyle modifications
  • 5.2.6. End User: Extending usage of metabolic disorders medications in clinics for small private practices to large multi-specialty facilities
  • 5.2.7. Distribution Channel: Rising popularity of online pharmacies owing to convenience and availability of options
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Metabolic Disorders Therapeutics Market, by Treatment Classifications

• 6.1. Introduction
• 6.2. Enzyme Replacement Therapies
• 6.3. Gene Therapies
• 6.4. Medications & Drugs
• 6.5. Small Molecule Therapy

7. Metabolic Disorders Therapeutics Market, by Disease Type

• 7.1. Introduction
• 7.2. Diabetes Mellitus
  • 7.2.1. Gestational Diabetes
  • 7.2.2. Type 1 Diabetes
  • 7.2.3. Type 2 Diabetes
• 7.3. Gaucher's Disease
• 7.4. Hemochromatosis
• 7.5. Hypercholesterolemia
• 7.6. Mitochondrial Disorders
• 7.7. Phenylketonuria (PKU)
• 7.8. Pompe Disease
• 7.9. Thyroid Disorders
  • 7.9.1. Hyperthyroidism
  • 7.9.2. Hypothyroidism
• 7.10. Urea Cycle Disorders
• 7.11. Wilson's Disease

8. Metabolic Disorders Therapeutics Market, by Therapeutic Areas

• 8.1. Introduction
• 8.2. Endocrine Disorders
• 8.3. Genetic Disorders
• 8.4. Nutritional Disorders

9. Metabolic Disorders Therapeutics Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral
• 9.4. Subcutaneous

10. Metabolic Disorders Therapeutics Market, by Patient Demographics

• 10.1. Introduction
• 10.2. Adult Patients
• 10.3. Geriatric Patients
• 10.4. Pediatric Patients

11. Metabolic Disorders Therapeutics Market, by End User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Homecare Settings
• 11.4. Hospitals
• 11.5. Specialty Centers

12. Metabolic Disorders Therapeutics Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Online Pharmacies
• 12.4. Retail Pharmacies

13. Americas Metabolic Disorders Therapeutics Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Metabolic Disorders Therapeutics Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Entero Therapeutics and Journey Therapeutics announce reverse merger to expand precision oncology and metabolic disorders therapies
  • 16.3.2. Chiesi Global Rare Diseases publishes phase 3 BRIGHT study results for pegunigalsidase alfa in fabry disease
  • 16.3.3. Sagimet's Denifanstat granted FDA advance therapy designation for MASH
  • 16.3.4. Amneal and Metsera collaborate to advance therapies for mbesity and Metabolic diseases
  • 16.3.5. Genespire secures USD 52.1m for gene therapy trial targeting rare metabolic disorder
  • 16.3.6. HAYA Therapeutics collaborates with Eli Lilly to target obesity and metabolic disorders using advanced rNA platform
  • 16.3.7. Roche acquires Carmot Therapeutics to advance in metabolic disease treatments
  • 16.3.8. ILBS and INSERM partner for advancements in metabolic disorder therapeutics
  • 16.3.9. Fractyl Health expands metabolic therapeutics pipeline with advanced clinical studies and preclinical results
  • 16.3.10. Marea Therapeutics launches with USD 190 million to develop next-gen cardiometabolic treatments
  • 16.3.11. Metsera strategic launch to innovate obesity and metabolic disease therapies
  • 16.3.12. Orchard Therapeutics U.S. launch of Lenmeldy for treating early-onset metachromatic leukodystrophy
  • 16.3.13. BioAge secures USD 170 million in Series D to advance obesity and metabolic therapies
  • 16.3.14. MIT secures USD 65.67 million for innovative metabolic disorder treatments
  • 16.3.15. Novo Nordisk collaborates with Omega Therapeutics and Cellarity on metabolic disorder innovations
  • 16.3.16. Chiesi Farmaceutici to acquire Amryt Pharma, enhancing rare disease therapeutics portfolio
• 16.4. Strategy Analysis & Recommendation
  • 16.4.1. F. Hoffmann-La Roche Ltd
  • 16.4.2. Lupin Limited
  • 16.4.3. Eli Lilly and Company
  • 16.4.4. Pfizer Inc.

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Acadia Pharmaceuticals Inc.
• 4. Amgen Inc.
• 5. Amicus Therapeutics, Inc.
• 6. Astellas Pharma Inc.
• 7. AstraZeneca plc
• 8. Bayer AG
• 9. Biocon Limited
• 10. BioMarin Pharmaceutical Inc.
• 11. Boehringer Ingelheim International GmbH
• 12. CHIESI Farmaceutici S.p.A.
• 13. Dr. Reddy's Laboratories Ltd.
• 14. Eli Lilly and Company
• 15. F. Hoffmann-La Roche Ltd
• 16. GlaxoSmithKline PLC
• 17. Glenmark Pharmaceuticals Limited
• 18. Johnson & Johnson Services, Inc.
• 19. Lupin Limited
• 20. Luye Pharma Group Ltd
• 21. Merck & Co., Inc.
• 22. Novartis AG
• 23. Novo Nordisk A/S
• 24. Otsuka Holdings Co., Ltd.
• 25. Pfizer Inc.
• 26. Recordati Industria Chimica e Farmaceutica S.p.A
• 27. Sanofi S.A.
• 28. Sumitomo Pharma Co., Ltd.
• 29. Sun Pharmaceutical Industries
• 30. Takeda Pharmaceutical Company Limited
• 31. Teva Pharmaceutical Industries Ltd.
• 32. Torrent Pharmaceuticals Ltd.